Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Myeloid Leukemia
100%
Co-treatment
100%
MK-0457
100%
Chronic Myelogenous Leukemia Cells
100%
Vorinostat
100%
VX-680
100%
HL-60 Cells
37%
OCI-AML3
37%
Apoptosis
25%
K562
25%
K562 Cells
25%
BCR-ABL
25%
Chronic Myeloid Leukemia
25%
Aurora Kinase A (AURKA)
25%
Viability Loss
25%
BaF3
25%
Attenuation
12%
Highly Active
12%
Induced Apoptosis
12%
Ectopic Overexpression
12%
Ectopic Expression
12%
Combined Treatment
12%
Phosphorylation
12%
Kinase Activity
12%
In Vivo Applications
12%
Mutant Forms
12%
Aurora Kinase Inhibitor
12%
Imatinib
12%
Imatinib Mesylate
12%
Endoreduplication
12%
Survivin
12%
Histone H3
12%
Aurora
12%
Kinase Substrate
12%
In Vivo Testing
12%
CD34+ Stem Cells
12%
Human Leukemia
12%
Hydroxamic Acid
12%
Synergistic Apoptosis
12%
Primary Leukemia Cells
12%
Aberrant Mitosis
12%
ProB
12%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Chronic Myelogenous Leukemia
100%
Leukemia Cell
100%
Vorinostat
100%
VX-680
100%
Programmed Cell Death
57%
Imatinib
28%
K562 Cells
28%
Aurora Kinase
28%
In Vitro
14%
Phosphotransferase
14%
Progenitor Cell
14%
Acute Leukemia
14%
Aurora Kinase Inhibitor
14%
Endoreduplication
14%
Survivin
14%
Histone H3
14%
Hydroxamic Acid
14%
Ectopic Expression
14%
Abelson Kinase
14%
Serine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chronic Myeloid Leukemia
100%
Vorinostat
100%
VX-680
100%
Imatinib
28%
Aurora Kinase
28%
Phosphotransferase
14%
Abelson Kinase
14%
Acute Leukemia
14%
Leukemia
14%
Serine
14%
Aurora Kinase Inhibitor
14%
Histone H3
14%
Survivin
14%
Hydroxamic Acid
14%